JP2023540041A5 - - Google Patents
Info
- Publication number
- JP2023540041A5 JP2023540041A5 JP2023513386A JP2023513386A JP2023540041A5 JP 2023540041 A5 JP2023540041 A5 JP 2023540041A5 JP 2023513386 A JP2023513386 A JP 2023513386A JP 2023513386 A JP2023513386 A JP 2023513386A JP 2023540041 A5 JP2023540041 A5 JP 2023540041A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- cells
- nucleotides
- unstimulated
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063071236P | 2020-08-27 | 2020-08-27 | |
| US63/071,236 | 2020-08-27 | ||
| PCT/US2021/047710 WO2022047003A1 (en) | 2020-08-27 | 2021-08-26 | Vector-free process for manufacture of engineered immune cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023540041A JP2023540041A (ja) | 2023-09-21 |
| JP2023540041A5 true JP2023540041A5 (https=) | 2024-07-09 |
Family
ID=80355669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513386A Pending JP2023540041A (ja) | 2020-08-27 | 2021-08-26 | 人工免疫細胞を製造するベクターフリーのプロセス |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240060089A1 (https=) |
| EP (1) | EP4204574A4 (https=) |
| JP (1) | JP2023540041A (https=) |
| KR (1) | KR20230056026A (https=) |
| CN (1) | CN116529385A (https=) |
| AU (1) | AU2021332334A1 (https=) |
| CA (1) | CA3188371A1 (https=) |
| WO (1) | WO2022047003A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| CN119930791A (zh) * | 2023-11-02 | 2025-05-06 | 重庆精准生物技术有限公司 | 特异性tigit肽段 |
| WO2026043478A1 (en) * | 2024-08-21 | 2026-02-26 | Fenwal, Inc. | Modified cells produced by bedside cell modification system and methods for using such cells |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018232356A1 (en) * | 2017-06-15 | 2018-12-20 | The Regents Of The University Of California | Targeted non-viral dna insertions |
| JP7101419B2 (ja) * | 2017-10-27 | 2022-07-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 内因性ｔ細胞受容体の標的置換 |
-
2021
- 2021-08-26 CN CN202180070934.0A patent/CN116529385A/zh active Pending
- 2021-08-26 AU AU2021332334A patent/AU2021332334A1/en active Pending
- 2021-08-26 WO PCT/US2021/047710 patent/WO2022047003A1/en not_active Ceased
- 2021-08-26 US US18/022,968 patent/US20240060089A1/en active Pending
- 2021-08-26 JP JP2023513386A patent/JP2023540041A/ja active Pending
- 2021-08-26 CA CA3188371A patent/CA3188371A1/en active Pending
- 2021-08-26 KR KR1020237009341A patent/KR20230056026A/ko active Pending
- 2021-08-26 EP EP21862715.6A patent/EP4204574A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230295296A1 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| US20260055157A1 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| AU2016380262B2 (en) | Methods of making chimeric antigen receptor -expressing cells | |
| US20220168389A1 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| CA3118616A1 (en) | Selection of improved tumor reactive t-cells | |
| EP4086342A1 (en) | Modified immune effector cell and preparation method therefor | |
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| CA3123392A1 (en) | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof | |
| CA2999070A1 (en) | Car t cell therapies with enhanced efficacy | |
| JP2017512054A (ja) | 三官能性ｔ細胞−抗原カプラ及び方法並びにこれらの使用 | |
| CA2961636A1 (en) | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy | |
| CA2982996A1 (en) | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells | |
| CA2981751A1 (en) | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell | |
| EP3765039A1 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| JP2023540041A5 (https=) | ||
| CA3159808A1 (en) | Bcma-targeted car-t cell therapy of multiple myeloma | |
| CA3154287A1 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| JP2024527408A (ja) | 記憶ナチュラルキラー細胞の拡大 | |
| KR20230084533A (ko) | 조작된 iPSC 및 보강된 면역 효과기 세포 | |
| JP2023540041A (ja) | 人工免疫細胞を製造するベクターフリーのプロセス | |
| US20240376216A1 (en) | Universal car-t cell targeting il13ralpha2, preparation method therefor and application thereof | |
| JP2025532633A (ja) | キメラ抗原受容体、及びキメラ抗原受容体を含む細胞 | |
| HK40068768A (en) | Methods of making chimeric antigen receptor-expressing cells | |
| HK40083622A (en) | Modified immune effector cell and preparation method therefor | |
| KR20220110199A (ko) | 태반-유래 동종이계 car-t 세포 및 이의 용도 |